Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Depreciation & Amortization (CF): 2018-2024

Historic Depreciation & Amortization (CF) for Eton Pharmaceuticals (ETON) over the last 7 years, with Dec 2024 value amounting to $1.1 million.

  • Eton Pharmaceuticals' Depreciation & Amortization (CF) rose 262.95% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year increase of 203.05%. This contributed to the annual value of $1.1 million for FY2024, which is 27.19% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $1.1 million for FY2024, which was up 27.19% from $901,000 recorded in FY2023.
  • In the past 5 years, Eton Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $1.8 million in FY2022 and a low of $462,000 during FY2021.
  • For the 3-year period, Eton Pharmaceuticals' Depreciation & Amortization (CF) averaged around $1.3 million, with its median value being $1.1 million (2024).
  • In the last 5 years, Eton Pharmaceuticals' Depreciation & Amortization (CF) soared by 283.98% in 2022 and then slumped by 49.21% in 2023.
  • Yearly analysis of 5 years shows Eton Pharmaceuticals' Depreciation & Amortization (CF) stood at $651,000 in 2020, then decreased by 29.03% to $462,000 in 2021, then soared by 283.98% to $1.8 million in 2022, then plummeted by 49.21% to $901,000 in 2023, then climbed by 27.19% to $1.1 million in 2024.